Skip to content

Magnetically Controlled Capsule Endoscope System in Stomach Examination of Moderately and Severely Obese Patients

A Prospective Study to Evaluate the Feasibility and Safety of Magnetically Controlled Capsule Endoscope System in Stomach Examination of Moderately and Severely Obese Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05459714
Enrollment
30
Registered
2022-07-15
Start date
2022-10-15
Completion date
2023-05-01
Last updated
2022-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

obesity, capsule endoscopy

Brief summary

This study is a prospective, multicenter clinical trial. The study is planned to be conducted at a qualified clinical trial center, and 30 subjects are planned to be enrolled to evaluate the feasibility and safety of magnetically controlled capsule endoscopy (MCE) system in the examination of gastric disorders in patients with moderate to severe obesity (BMI ≥ 35 kg/m2).

Detailed description

Metabolic surgery, as one of the most important treatments for obesity, has been widely used worldwide. Esophagogastroduodenoscopy (EGD) is mostly used in the perioperative preoperative application of metabolic surgery to improve or exclude preoperative diagnosis, including gastrointestinal tumors, various types of upper GI mucosal lesions, esophagitis, esophageal hiatal hernia, gastrointestinal interstitial tumors, etc. However, EGD is an invasive examination and can cause discomfort without anesthesia, resulting in low patient compliance. In 2013, ANKON took the lead in developing the world's first capsule endoscope system that utilizes precise multi-dimensional rotational movement of a robotic arm and adaptive matching to achieve precise magnetic control, which is convenient for observing specific lesions from an appropriate angle and has been shown to have high diagnostic accuracy for gastric diseases (highly consistent with EGD, with sensitivity and specificity of 90.4% and 95.7%, respectively, and accuracy of 93.4%). It has been clinically proven that MCE is safe and effective in the upper gastrointestinal tract, but there is a lack of clinical systematic studies on its application to moderately and severely obese people.In summary, this exploratory study is designed to preliminarily verify the clinical feasibility and safety of MCE for upper gastrointestinal examination in moderately obese people (BMI ≥ 35 kg/m2).

Interventions

DEVICEMCE for obese patients

Sequence of stomach examination: The stomach examination is performed sequentially according to the order of fundus, cardia, gastric body, angulus, antrum, and pylorus, which should ensure the integrity of the observation of each part of the stomach and achieve the purpose of comprehensive observation by means of different observation distances such as distant view and close view, and different observation angles such as front and side.

Sponsors

Shanghai 6th People's Hospital
CollaboratorOTHER
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
CollaboratorOTHER
Changhai Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Clinical diagnosis of obesity: BMI ≥ 35kg/m2; 2. Be scheduled to undergo gastric examination; 3. Be able to provide informed consent.

Exclusion criteria

1\. With swallowing obstruction or disorders; 2. With known or suspected gastrointestinal obstruction, stenosis and fistula; 3. Have no conditions for surgery or refuse to undergo any abdominal surgery; 4. Be allergic to or have other known contraindication or intolerance to the drug used in the study; 5. With pacemakers or other electronic devices such as electronic cochlear implants, implanted magnetic metal drug infusion pumps, neurostimulators, and magnetic metal foreign bodies; 6. Women during pregnancy; 7. Currently enrolled in another clinical trial of a drug or device; 8. Other conditions determined by the investigator to be inappropriate for enrollment. \-

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Complete Observation2 weeksThe number of participants with complete observation. Complete observation of the mucosa means over 90% of the mucosa observed in gastric cardia, fundus, body, angulus, antrum and pylorus.

Secondary

MeasureTime frameDescription
Gastric Examination Time2 weeksGastric examination time was defined as the time taken for the endoscopist to complete the gastric examination to his or her satisfaction
The Total Number of Patients Who Who Had a Diagnosis of Positive Findings2 weeksIt was calculated using the following formula: number of patients with positive findings divided by the total number of patients that underwent examination.
Evaluation of patient satisfaction through questionaires2 weeksThe investigators use a satisfaction questionnaire to evaluate the satisfaction of each patient, including ease of capsule swallowing, discomfort during the examination, discomfort after the examination and comfort level of MCE examination.

Countries

China

Contacts

Primary ContactZhuan Liao
liaozhuan@smmu.edu.cn86-21-31161004

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026